Related Experiment Video
Updated: Aug 18, 2025
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
Current Management Options for Patients with Retinitis Pigmentosa
1Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Irving Medical Center, New York, NY, USA. aat2164@columbia.edu.
Insights
Retinitis pigmentosa (RP) is an inherited retinal disease affecting 1 in 4000 people, often leading to blindness. While no cure exists, current care includes management and rehabilitation, with emerging gene therapies and prostheses offering new hope.
Area of Science:
- Ophthalmology
- Genetics
- Retinal Diseases
Background:
- Retinitis pigmentosa (RP) is a group of inherited retinal diseases with a global prevalence of approximately 1 in 4000.
- RP causes progressive vision loss, potentially leading to blindness by age 30.
- Currently, no definitive cure for RP exists, impacting many individuals worldwide.
Purpose of the Study:
- To review current standards of care for retinitis pigmentosa (RP).
- To discuss therapeutic strategies including nutritional supplementation and management of associated ocular conditions.
- To explore emerging treatments such as gene therapy, visual prostheses, and stem cell therapy for RP.
Main Methods:
- Literature review of current and emerging therapeutic strategies for retinitis pigmentosa (RP).
- Discussion of established care protocols, including monitoring, management of complications, and supportive therapies.
- Overview of recent advancements in FDA-approved treatments for RP.
Main Results:
- Nutritional supplementation offers benefits only for specific rare forms of RP.
- Standard care for RP involves regular monitoring, managing secondary conditions like macular edema and cataracts, and providing genetic counseling and low vision rehabilitation.
- Gene therapy, visual prostheses, and stem cell therapy are emerging FDA-approved treatments, though not yet widely implemented.
Conclusions:
- Retinitis pigmentosa (RP) management relies on supportive care and rehabilitation due to the lack of a universal cure.
- Emerging therapies like gene therapy and visual prostheses represent significant advancements in treating RP.
- Further research and wider adoption of novel treatments are crucial for improving outcomes for RP patients.
Abstract:
With an estimated prevalence of 1 in 4000 worldwide [1], retinitis pigmentosa (RP) comprises a spectrum of progressive inherited retinal disorders that can lead to blindness as early as age 30 [2]. Despite its relatively high prevalence and devastating consequences, RP does not have a definitive cure. Therapeutic attempts have been made with nutritional supplementation, but these strategies only have proven benefit in a limited number of patients with rare forms of RP. Thus, current standards of care involve regular follow-up, management of associated ocular pathology such as macular edema and cataracts, and genetic counseling and low vision rehabilitation. In recent years, gene therapy, visual prostheses, and stem cell therapy have emerged as FDA-approved treatments for RP, but these options are not yet widely used. Herein, this chapter will discuss the therapeutic strategies listed above that comprise the current standards of care and briefly discuss some emerging options.
